Study of a new drug (OTP-01) for advanced solid tumors
Part of Cancer clinical trials.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that has spread or cannot be removed with surgery.
- You must have tried at least one standard cancer treatment that no longer works or was not tolerated.
- You must be able to perform everyday activities with minimal help (ECOG score 0 or 1).
- You must have at least a 3-month life expectancy.
- You must be willing to provide a tumor sample (from a past biopsy or a new one).
- You cannot have had certain other cancer treatments within the last few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
This trial tests a new treatment that combines two drugs—OVV-01 (injected directly into tumors) and AK112 (given by vein)—for advanced solid cancers that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.